In one of the most closely-watched biotech policy initiatives underway in Washington, President Obama appears ready to call for a regulatory pathway to approve generic biotech therapies, also known as biosimilars. That move would have a major impact on a biotech company like Amgen, which has anemia drugs that will quickly face new generic competition. And it will be a boon to biopharma companies like Merck, which are jumping into this space in a big way. Report